NASDAQ:ECYT
Delisted

Endocyte Fund Signals

$23.99
+0 (+0%)
At Close: Jan 18, 2019

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 3.030 43 days ( -1.61 % )
Last Price $23.99 0 %
High/ Low $23.99 - $23.99 0%
Chg 7 Days N/A $23.99 $23.99
Chg 30 Days -0.0417 % $24.00 $23.99
Chg 12 mos 507.34 % $3.95 $23.99
Trend - 3 mos 2.44 % Width: 2.45 %
Trend - 12 mos 281.83 % Width: 41.36 %
Pred. range - 3 mos $24.31 - $24.91 1.34 % - 3.83 %
Pred. range - 12 mos $79.47 - $112.34 231.26 % - 368.27 %
Short MA avg 3 mos Sell 2018-12-27 - 16 days
Long MA avg 3 mos Sell 0000-00-00 - N/A days
Short/Long MA avg 3 mos Sell 0000-00-00 - N/A days
Short MA avg 12 mos Sell 2019-01-04 - 11 days
Long MA avg 12 mos Buy 2018-10-17 - 64 days
Short/Long MA avg 12 mos Buy 2018-10-18 - 63 days
Pivot Short Sell 2018-12-19 - 21 days
Bollinger Sell 0000-00-00 - N/A days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Endocyte

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of ad... ECYT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT